Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma
复制标题
DOI：
10.1007/s10637-012-9889-4
复制
发表时间：
2013-04-01
影响因子：
3.4
通讯作者：
Kim, Won Seog
中科院分区：
文献类型：
--
作者：
Ahn, Hee Kyung;Kim, Seok Jin;Kim, Won Seog
结外自然杀伤/T细胞淋巴瘤（ENKL）预后不良。尽管L-天冬酰胺酶作为一线治疗已显示出有希望的疗效，但目前在进展至含L-天冬酰胺酶的方案后没有治疗选择。我们报告了含吉西他滨治疗复发性或难治性ENKL患者的结果。我们回顾性分析了2005年至2011年期间接受含吉西他滨方案治疗的20例难治性或复发性ENKL患者。总缓解率为40%（20例患者中的8例），其中完全缓解（CR）率为20%（n = 4），部分缓解（PR）率为20%（n = 4）。4例完全缓解者的无病状态超过7个月，包括2例分别接受自体干细胞移植巩固和L-天冬氨酸酶维持治疗的患者。20例患者的中位无进展生存期为2.3个月;然而，8例应答者（CR和PR）的中位无进展生存期为7.3个月。在分析时，8名应答者的中位总生存期尚未达到。吉西他滨在一个预先治疗的ENKL患者亚组中有效，可视为一种挽救治疗选择。
Extranodal natural killer/T-cell lymphoma (ENKL) has a dismal prognosis. Although L-asparaginase has shown promising efficacy as a frontline therapy, currently there are no treatment options after progression to an L-asparaginase-containing regimen. We report the results of gemcitabine-containing therapy in patients with relapsed or refractory ENKL. We retrospectively reviewed 20 patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen between 2005 and 2011. The overall response rate was 40 % (8 of 20 patients) with a complete response (CR) rate of 20 % (n = 4) and a partial response (PR) rate of 20 % (n = 4). Four complete responders had a disease-free status for more than 7 months including two patients received autologous stem cell transplantation consolidation and L-aspraginase maintenance, respectively. The median progression-free survival of the 20 patients was 2.3 months; however, it was 7.3 months for eight responders (CR and PR). The median overall survival of the eight responders had not been reached at the time of analysis. Gemcitabine was effective in a subset of pretreated ENKL patients and can be considered as a salvage option.